Current Report Filing (8-k)
July 01 2021 - 04:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 30, 2021
RAPT Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
001-38997
|
|
47-3313701
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
561 Eccles Avenue
South San Francisco, CA
|
|
94080
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(650) 489-9000
(Registrants Telephone Number, Including Area Code)
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, $0.0001 par value per share
|
|
RAPT
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
(b)
On June 30, 2021, Peter Svennilson notified RAPT Therapeutics, Inc. (the Company) of his decision to resign from the board of directors of the
Company, effective as of June 30, 2021. Mr. Svennilsons resignation was not the result of any disagreement with the Company on any matter relating to the Companys operations, policies or practices.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Dated: July 1, 2021
|
|
|
|
RAPT THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Rodney Young
|
|
|
|
|
|
|
Rodney Young
|
|
|
|
|
|
|
Chief Financial Officer
|
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Feb 2024 to Mar 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Mar 2023 to Mar 2024